The Cancer Trials Australia (CTA) Board has announced the appointment of ONJCRI's Professor Andrew Scott as Chairperson. Prof. Scott was appointed following the departure of former Chair Prof. Mark Rosenthal.
Prof. Scott currently holds appointments as the Scientific Director of PET, Department of Molecular Imaging and Therapy at Austin Health, and Head of the Tumour Targeting Laboratory at the Olivia Newton-John Cancer Research Institute. He is one of Australia’s top clinician scientists with extensive experience in both pre-clinical and clinical drug development.
Prof. Scott has served on the CTA Board since 2004, and is also involved in a variety of significant organisations related to medical research.
CTA CEO Marcus Clark says “Andrew’s experience with CTA over a long period together with his understanding of working with our key partners in drug development will provide the continuity of direction we have had with Mark.”
Prof. Scott highlights the appointment as “an opportunity to enhance the outstanding reputation of oncology research and clinical trials in Australia. CTA provides invaluable linkages between researchers and clinicians, and facilitates clinical trials of the most promising new therapies for our cancer patients.”
The appointment is a significant recognition of Prof Scott’s contribution to the growth and development of this research field.
WHO IS CANCER TRIALS AUSTRALIA?
Cancer Trials Australia (CTA) is a not-for-profit organisation that regulates and manages cancer clinical trials, provides research governance and advisory services to its members, including research institutes, major hospitals such as the Alfred, the Austin and St Vincent’s, and other health organisations.